Tarsus Pharmaceuticals (TARS) Preferred Stock Liabilities (2019 - 2020)
Tarsus Pharmaceuticals (TARS) recorded quarterly Preferred Stock Liabilities of $103.2 million in Q3 2020, up 62.71% quarter-over-quarter from $63.4 million in Q2 2020, and up 2794.47% on a YoY basis from $3.6 million in Q4 2019.
Tarsus Pharmaceuticals (TARS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Tarsus Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $103.2 million for Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 2794.47% year-over-year to $103.2 million; the TTM figure through Sep 2020 stood at $103.2 million (up 2794.47% YoY), while the FY2019 annual figure was $63.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $103.2 million for Q3 2020 at Tarsus Pharmaceuticals, up from $63.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $103.2 million in Q3 2020 to a low of $3.6 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 103.16 Mn |
| Jun 30, 2020 | 63.40 Mn |
| Mar 31, 2020 | 63.40 Mn |
| Dec 31, 2019 | 63.40 Mn |
| Sep 30, 2019 | 3.56 Mn |